title: [Functional regulation of genome with peptide bioregulators by hypertrophic cardiomyopathy (by patients and relatives)].
abstract: In this paper, a comparative study of the functional genome indicators using lymphocyte cultures of patients with hypertrophic cardiomyopathy (HCM) and their first relatives. Studies conducted both in intact cultures and cultures exposed to the influence of peptide - bioregulators Epithalon, Vilon and Livagen. Last (Livagen) tested at separate and joint application with cobalt chloride salt. As indicated according to the results of the analysis, the cells of the individuals with HCM and their first relatives were characterized by higher frequency of spontaneous quantitative - structural disorders in comparison with the cells of healthy individuals. The findings suggest a different effect of bioregulators. The most effective protective action in relation normalization of functional parameters of the genome shows Epithalon for lowering the level of chromosomal instability in patients with hypertrophic cardiomyopathy and relatives of patients with HCM. On the basis of identified protective action Epithalon concludes prospects of its application in the development of preventive measures for individuals at increased risk of morbidity HCM.
authors.forename: T A
authors.initials: TA
authors.lastname: Dzhokhadze
authors.forename: T Zh
authors.initials: TZh
authors.lastname: Buadze
authors.forename: M N
authors.initials: MN
authors.lastname: Gaĭozishvili
authors.forename: M A
authors.initials: MA
authors.lastname: Rogava
authors.forename: T A
authors.initials: TA
authors.lastname: Lazhava
mesh_terms: D000782:Aneuploidy; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D002843:Chromatin / Q000187:drug effects; D002869:Chromosome Aberrations / Q000187:drug effects*; D004151:Dipeptides / Q000008:administration & dosage; D005260:Female; D015894:Genome, Human / Q000187:drug effects; D006801:Humans; D008214:Lymphocytes / Q000166:cytology* / Q000187:drug effects; D008297:Male; D009842:Oligopeptides / Q000008:administration & dosage; D010455:Peptides / Q000008:administration & dosage; D061251:Primary Cell Culture
chemical_list: D002843:Chromatin; D004151:Dipeptides; C473185:Livagen; D009842:Oligopeptides; D010455:Peptides; C415909:lysylglutamic acid; C421253:alanyl-glutamyl-aspartyl-glycine